CELLULAR KINETICS OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, LISOCABTAGENE MARALEUCEL (LISO-CEL) AND ITS ASSOCIATION WITH EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

被引：0
|
作者：
Nishii, R. [1 ]
Lin, H. [1 ]
Chen, W. [1 ]
Balasubramanian, N. [1 ]
Cummings, J. [1 ]
Farazi, T. [1 ]
Fasan, O. [1 ]
Vedal, M. [1 ]
Lymp, J. [1 ]
Ogasawara, K. [1 ]
机构：
[1] Bristol Myers Squibb, Summit, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-016
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [1] Treatment with Iberdomide Enhances Antitumor Function of the Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel)
    Qin, Jim
    Jiang, Yue
    Barajas, Brook
    Kasibhatla, Shailaja
    Ports, Michael
    MOLECULAR THERAPY, 2020, 28 (04) : 499 - 500
  • [2] TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Borchmann, Peter
    Morschhauser, Franck
    Dahiya, Saurabh
    Palomba, M. Lia
    Garcia-Sancho, Alejandro Martin
    Reguera Ortega, Juan Luis
    Kuruvilla, John
    Jaeger, Ulrich
    Cartron, Guillaume
    Izutsu, Koji
    Dreyling, Martin
    Kahl, Brad
    Ghesquieres, Herve
    Ardeshna, Kirit
    Goto, Hideki
    Barbui, Anna Maria
    Abramson, Jeremy S.
    Fleury, Isabelle
    Mielke, Stephan
    Farazi, Thalia
    Fasan, Omotayo
    Lymp, James
    Vedal, Min
    Nishii, Rina
    Avilion, Ariel
    Papuga, Jessica
    Nastoupil, Loretta J.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 142 - 143
  • [3] Impact of bridging therapy (BT) on lisocabtagene maraleucel (liso-cel) treatment in patients (pt) with R/R follicular lymphoma (FL)
    Luis Reguera, Juan
    Garcia-Sancho, Alejandro Martin
    Kuruvilla, John
    Izutsu, Koji
    Maria Barbui, Anna
    Peter, Borchmann
    Mielke, Stephan
    Lia Palomba, Maria
    Cartron, Guillaume
    Ghesquieres, Herve
    Goto, Hideki
    Varadarajan, Indumathy
    Farazi, Thalia
    Hui Kao, Grace Shih
    Vedal, Min
    Nishii, Rina
    Papuga, Jessica
    Morschhauser, Franck
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Martinez-Prieto, Marcela
    Bollu, Vamsi
    Ma, Qiufei
    Kuzan, David
    Maziarz, Richard T.
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)
    Balasubramanian, N.
    Cummings, J.
    Lin, H.
    Raviele, A.
    Peng, L.
    Omidpanah, A.
    Espinola, R.
    Kostic, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S54 - S54
  • [6] TREATMENT WITH CC-99282 ENHANCES ANTITUMOR FUNCTION OF THE ANTI-CD19 CAR T CELL THERAPY LISOCABTAGENE MARALEUCEL (LISO-CEL)
    Brahmandam, Archana
    Qin, Jim
    Kim, Susan
    Jiang, Yue
    Barajas, Brook
    Carrancio, Soraya
    Peiser, Leanne
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A117 - A117
  • [7] Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001.
    Wang, Michael
    Gordon, Leo I.
    Palomba, Maria Lia
    Abramson, Jeremy S.
    Andreadis, Charalambos
    Ghosh, Nilanjan
    Lunning, Matthew Alexander
    Maloney, David G.
    Farazi, Thalia Andrea
    Garcia, Jacob
    Xie, Benhuai
    Newhall, Kathryn J.
    Dehner, Christine
    Siddiqi, Tanya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel (Liso-Cel) in TRANSCEND NHL 001
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 8 - 9
  • [9] COST EFFECTIVENESS OF THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TREATMENT LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE (2L) TREATMENT OF RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN SWITZERLAND
    Deger, K.
    Oniangue-Ndza, C.
    Elsada, A.
    Litkiewicz, M.
    Villalobos, Franco C.
    Sorensen, S.
    VALUE IN HEALTH, 2023, 26 (12) : S152 - S153
  • [10] Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma
    Fried, Shalev
    Shkury, Eden
    Itzhaki, Orit
    Sdayoor, Inbal
    Yerushalmi, Ronit
    Shem-Tov, Noga
    Danylesko, Ivetta
    Jacoby, Elad
    Shouval, Roni
    Kedmi, Meirav
    Marcus, Ronit
    Nagler, Arnon
    Shimoni, Avichai
    Avigdor, Abraham
    LEUKEMIA & LYMPHOMA, 2023, 64 (12) : 1956 - 1963
12345